291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). - Harbeck, N.; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.B.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Zurawski, B.; Escrivá-de-Romaní, S.; et al. (Annals of Oncology, 2025)